NEW DELHI—Sun Pharmaceutical Industries announced that it has completed the acquisition of U.S.-based eyecare specialist Ocular Technologies Sarl, a portfolio company of Auven Therapeutics.

As VMail previously reported, Sun Pharma was set to pay Auven $40 million upfront, plus contingent development milestones and sales milestones as well as tiered royalty on Seciera sales, which is currently in Phase-3 confirmatory clinical trials.

“All the necessary formalities for closure of the said transaction have been concluded and the company has successfully completed the acquisition of Ocular Technologies Sarl, on December 15, 2016,” Sun Pharmaceutical Industries said in a BSE filing.